Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter Observational Study.

Vaccines (Basel) · 2021 · PMC8541274 · PMID 34696229

Europe PMC DOI

hedged sentence

0.0750

closest p · 1.5× alpha

0.0750

boldest claim

The sentences

did not reach statistical significancep = 0.075so close (0.05 < p ≤ 0.1)

Adenocarcinoma demonstrated a shorter PFS trend, which did not reach statistical significance ( p = 0.075).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.